1Conjeevaram HS;Lok AS.Management of chronic hepatitis B[J],2003(zk).
2Gandhi MJ;Yang GG;McMahon BJ.Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viremia by PCR in Alaska Native HBV carriers who have seroconverted[J],2000.
3Adachi H;Kaneko S;Matsushita E.Clearance of HBsAg in seven patients with chronic hepatitis B[J],1992.
4Locarnini S;Birch C.Antiviral chemotherapy for chronic hepatitis B infection:lessons learned from treating HIV-infected patients[J],1999.
5Chu CJ;Hussain M;Lok AS.Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection[J],2002.
6Dienstag JL;Goldin RD;Heathcote EJ.Histological outcome during long-term lamivudine therapy[J],2003(1).
7Hunt CM;McGill JM;Allen MI.Clinical relevance of hepatitis B viral mutations[J],2000(5).
8Tassopoulos NC;Volpes R;Pastore G.Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B[J],1999(29).
9Liaw YF;Chien RN;Yeh CT.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy[J],1999(2).
10Liaw YF.Hepatitis B flares and hepatitis B e antigen seroconversion:implication in anti-hepatitis B virus therapy[J],2003(3).
